Tags

Type your tag names separated by a space and hit enter

Causality assessment in drug-induced liver injury.
Semin Liver Dis. 2009 Nov; 29(4):348-56.SL

Abstract

Assigning causality in drug-induced liver injury (DILI) due to a particular medication or herbal and dietary supplement relies on clinical history, exclusion of competing causes, prior reports of DILI, and judgment-no objective laboratory or histological tests exist to confirm a diagnosis of suspected DILI. Current causality assessment instruments are based on algorithmic scoring systems but are not widely used. Expert opinion remains the gold standard, but is cumbersome and has limited reproducibility. The lack of a valid and widely available causality assessment method hinders the identification of genetic and biochemical markers that may help better define DILI. Emerging technologies in pharmacogenomics and toxicogenomics may identify such markers if well-defined DILI cases and controls can provide tissue samples for analysis. In this article, current causality assessment instruments, including expert opinion, are discussed, and the necessary features for an improved instrument are provided.

Authors+Show Affiliations

UNC Liver Program, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina 27599-7584, USA. paul_hayashi@med.unc.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19826968

Citation

Hayashi, Paul H.. "Causality Assessment in Drug-induced Liver Injury." Seminars in Liver Disease, vol. 29, no. 4, 2009, pp. 348-56.
Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis. 2009;29(4):348-56.
Hayashi, P. H. (2009). Causality assessment in drug-induced liver injury. Seminars in Liver Disease, 29(4), 348-56. https://doi.org/10.1055/s-0029-1240003
Hayashi PH. Causality Assessment in Drug-induced Liver Injury. Semin Liver Dis. 2009;29(4):348-56. PubMed PMID: 19826968.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Causality assessment in drug-induced liver injury. A1 - Hayashi,Paul H, Y1 - 2009/10/13/ PY - 2009/10/15/entrez PY - 2009/10/15/pubmed PY - 2009/12/18/medline SP - 348 EP - 56 JF - Seminars in liver disease JO - Semin. Liver Dis. VL - 29 IS - 4 N2 - Assigning causality in drug-induced liver injury (DILI) due to a particular medication or herbal and dietary supplement relies on clinical history, exclusion of competing causes, prior reports of DILI, and judgment-no objective laboratory or histological tests exist to confirm a diagnosis of suspected DILI. Current causality assessment instruments are based on algorithmic scoring systems but are not widely used. Expert opinion remains the gold standard, but is cumbersome and has limited reproducibility. The lack of a valid and widely available causality assessment method hinders the identification of genetic and biochemical markers that may help better define DILI. Emerging technologies in pharmacogenomics and toxicogenomics may identify such markers if well-defined DILI cases and controls can provide tissue samples for analysis. In this article, current causality assessment instruments, including expert opinion, are discussed, and the necessary features for an improved instrument are provided. SN - 1098-8971 UR - https://www.unboundmedicine.com/medline/citation/19826968/Causality_assessment_in_drug_induced_liver_injury_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0029-1240003 DB - PRIME DP - Unbound Medicine ER -